Inactivated poliovirus vaccine: current production methods and new developments.
The biotechnologic developments during the last decade have led to the production of inactivated poliovirus vaccine (IPV) on an industrial scale and at economically acceptable costs. Replacement of primary monkey kidney cells by subcultured monkey kidney, Vero, or human diploid cells as substrate for virus multiplication as well as the introduction of the microcarrier culture technique have made cell and virus cultivation in large fermentors of 100-1,000 liters feasible. Procedures for processing virus harvests into highly concentrated purified vaccines were developed; also, the safety and potency control tests were improved and simplified. It has been demonstrated that these more potent poliovirus vaccines, either alone or in combination with diphtheria-tetanus-pertussis vaccine, induce a high immunity with reduced vaccination schedules. The overall costs of vaccination will be reduced considerably in this way. In addition, the results of biochemical and immunologic studies indicate that neutralizing antibodies can be induced by the viral proteins alone. These findings open up promising perspectives for production of subunit poliovirus vaccines with use of recombinant DNA and synthetic antigen, a method that has already proved feasible for producing vaccine against foot and mouth disease. These new techniques may lead to a further reduction of production costs and will improve the safety of the vaccine.
D000818:Animals; D000956:Antigens, Viral / Q000032:analysis; D002478:Cells, Cultured; D003365:Costs and Cost Analysis; D004168:Diphtheria Toxoid / Q000302:isolation & purification; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations / Q000302:isolation & purification; D000882:Haplorhini; D006801:Humans; D010567:Pertussis Vaccine / Q000302:isolation & purification; D011054:Poliovirus Vaccine, Inactivated / Q000276:immunology / Q000302:isolation & purification* / Q000592:standards; D013745:Tetanus Toxoid / Q000302:isolation & purification; D014613:Vaccines, Attenuated / Q000302:isolation & purification
D000956:Antigens, Viral; D004168:Diphtheria Toxoid; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations; D010567:Pertussis Vaccine; D011054:Poliovirus Vaccine, Inactivated; D013745:Tetanus Toxoid; D014613:Vaccines, Attenuated